A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML.

MLA

Webster, Jonathan A., et al. “A Randomized, Phase II Trial of Adjuvant Immunotherapy with Durable TKI-Free Survival in Patients with Chronic Phase CML.” Leukemia Research, vol. 111, Dec. 2021, p. 106737. EBSCOhost, https://doi.org/10.1016/j.leukres.2021.106737.

APA

Webster, J. A., Robinson, T. M., Blackford, A. L., Warlick, E., Ferguson, A., Borrello, I., Zahurak, M., Jones, R. J., & Smith, B. D. (2021). A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML. Leukemia Research, 111, 106737. https://doi.org/10.1016/j.leukres.2021.106737

Chicago

Webster, Jonathan A, Tara M Robinson, Amanda L Blackford, Erica Warlick, Anna Ferguson, Ivan Borrello, Marianna Zahurak, Richard J Jones, and B Douglas Smith. 2021. “A Randomized, Phase II Trial of Adjuvant Immunotherapy with Durable TKI-Free Survival in Patients with Chronic Phase CML.” Leukemia Research 111 (December): 106737. doi:10.1016/j.leukres.2021.106737.